Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feverfew extract is a preparation derived from the leaves of the feverfew plant (*Tanacetum parthenium*). It contains active compounds such as parthenolide, flavonoid glycosides, and pinenes[7]. Feverfew extract is primarily used as a dietary supplement for the prophylaxis of migraine headaches, with some evidence suggesting it can reduce the frequency and pain intensity of attacks[1][4][10]. Proposed mechanisms include inhibition of serotonin release from platelets, inhibition of neutrophil granule release, modulation of the GABAergic system (based on preclinical data), anti-inflammatory effects (by inhibiting pro-inflammatory cytokines and prostaglandin synthesis), and antispasmodic/vasorelaxant actions[4][5][7][8][10]. Laboratory studies suggest antibacterial, antiprotozoal, and antioxidant properties, but these are not clinically established[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on feverfew extract.